About Generate Biomedicines
Generate Biomedicines is a company based in Somerville (United States) founded in 2018 by Gevorg Grigoryan, Molly Gibson, and Noubar Afeyan.. Generate Biomedicines has raised $693 million across 4 funding rounds from investors including Amgen, Fidelity Investments and T. Rowe Price. Generate Biomedicines offers products and services including Generate Platform, Antibodies, Peptides, and Enzymes. Generate Biomedicines operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Biogen, ADMA Biologics and Chimerix, among others.
- Headquarter Somerville, United States
- Founders Gevorg Grigoryan, Molly Gibson, Noubar Afeyan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Generate Biomedicines, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$693 M (USD)
in 4 rounds
-
Latest Funding Round
-
Investors
Amgen
& 13 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Generate Biomedicines
Generate Biomedicines offers a comprehensive portfolio of products and services, including Generate Platform, Antibodies, Peptides, and Enzymes. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI-driven tool for generating novel proteins and medicines for therapeutics.
Generated antibodies targeting viral threats like SARS-CoV-2.
Custom peptides for advanced drug development applications.
Engineered enzymes for improving therapeutic modalities and success rates.
Unlock access to complete
Unlock access to complete
Funding Insights of Generate Biomedicines
Generate Biomedicines has successfully raised a total of $693M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(01 Sep 2020)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Series C - Generate Biomedicines | Valuation |
investors |
|
| Sep, 2023 | Amount | Series C - Generate Biomedicines | Valuation | Amgen , Pictet Group | |
| Nov, 2021 | Amount | Series B - Generate Biomedicines | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Generate Biomedicines
Generate Biomedicines has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, Fidelity Investments and T. Rowe Price. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Generate Biomedicines
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Generate Biomedicines
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Generate Biomedicines Comparisons
Competitors of Generate Biomedicines
Generate Biomedicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Biogen, ADMA Biologics and Chimerix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Generate Biomedicines
Frequently Asked Questions about Generate Biomedicines
When was Generate Biomedicines founded?
Generate Biomedicines was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Generate Biomedicines located?
Generate Biomedicines is headquartered in Somerville, United States. It is registered at Somerville, Massachusetts, United States.
Who is the current CEO of Generate Biomedicines?
Michael Nally is the current CEO of Generate Biomedicines.
Is Generate Biomedicines a funded company?
Generate Biomedicines is a funded company, having raised a total of $693M across 4 funding rounds to date. The company's 1st funding round was a Series B of $370M, raised on Sep 01, 2020.
What does Generate Biomedicines do?
Generate Biomedicines was founded in 2018 and is based in Somerville, United States. Operations center on a generative biology platform that employs machine learning and biological engineering to produce protein-based therapeutics. Medicines are created across various therapeutic modalities, with efforts directed toward expanding technical capabilities in drug development within the biotechnology sector.
Who are the top competitors of Generate Biomedicines?
Generate Biomedicines's top competitors include Moderna, ADMA Biologics and Adaptive Biotechnologies.
What products or services does Generate Biomedicines offer?
Generate Biomedicines offers Generate Platform, Antibodies, Peptides, and Enzymes.
Who are Generate Biomedicines's investors?
Generate Biomedicines has 14 investors. Key investors include Amgen, Fidelity Investments, T. Rowe Price, Flagship Pioneering, and Arch Venture Partners.